Medesis shoots up on push for antinuclear drugs development

Medesis Pharma SA

05/04/2022 08:43

** Shares in Medesis Pharma  ALMDP.PA  soar more than 20%
after the French biotechnology group said it planned to
accelerate the development of its antinuclear products
 urn:newsml:reuters.com:*:nFWN2W20Z6
    ** The three drugs are specifically intended for the
treatment of large populations contaminated or irradiated after
a civil or military nuclear accident, the company says
    ** "To date, there is no suitable treatment for a serious
nuclear accident," Medesis Pharma says, announcing funding
requests to France's Defense Innovation Agency (DIA)
    ** It adds the products are relevant to the crisis in
Ukraine, which has raised the possibility of nuclear war, and
French plans to ramp up nuclear power  urn:newsml:reuters.com:*:nL5N2VK549
    ** The stock of Medesis Pharma, which is down around 30%
year-to-date, is heading for its best day since September 2021

 (Reporting by Juliette Portala and Sarah Morland)
 ((juliette.portala@tr.com))